Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the drug ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.